LNC
BIO icon

Lincoln National Corp’s Bio-Rad Laboratories Class A BIO Stock Holding History

Lincoln National Corp’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-694
Closed -$249K – 1107
2023
Q3 		$249K Sell
694
-5
-0.7% -$1.93K 0.01% 874
2023
Q2 		$265K Sell
699
-30
-4% -$12.2K 0.01% 850
2023
Q1 		$349K Buy
729
+38
+5% +$17.8K 0.01% 719
2022
Q4 		$291K Buy
+691
New +$279K 0.01% 728

Other funds holding BIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VAM
Veritas Asset Management London, United Kingdom $5.9B AUM 3.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Lincoln National Corp's BIO Position: Q4 2023 in Review

Lincoln National Corp sold out of Bio-Rad Laboratories Class A (BIO) in Q4 2023, closing a stake of 694 shares — an estimated $249K sold.

Lincoln National Corp first reported a position in BIO in Q4 2022 and held it in 4 quarters. The position peaked at $349K in Q1 2023. 483 funds tracked by Wall St. Rank hold BIO as of Q4 2023.

  • Lincoln National Corp reported no remaining Bio-Rad Laboratories Class A position as of Q4 2023 after selling out during the quarter.
  • Lincoln National Corp sold 694 Bio-Rad Laboratories Class A shares in Q4 2023, an estimated $249K.
  • Lincoln National Corp first reported a position in Bio-Rad Laboratories Class A in Q4 2022 and held it in 4 quarters.
  • Lincoln National Corp's Bio-Rad Laboratories Class A position peaked at $349K in Q1 2023.
  • 483 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q4 2023.

Based on Lincoln National Corp's 13F filing for Q4 2023, filed 6 Feb 2024.